Event:
On March 29, 2022, in order to implement the decision and deployment of the CPC Central Committee and the State Council on the work of traditional Chinese medicine and clarify the development objectives, tasks and key measures of traditional Chinese medicine during the 14th Five Year Plan period, the general office of the State Council issued the 14th five year plan for the development of traditional Chinese medicine.
Comments:
The plan puts forward future development goals and multiple development tasks. The plan proposes that by 2025, the health service capacity of traditional Chinese medicine will be significantly enhanced, the high-quality development policy and system of traditional Chinese medicine will be further improved, the revitalization and development of traditional Chinese medicine will achieve positive results, and its unique advantages in the construction of a healthy China will be brought into full play. At the same time, aiming at the service system of traditional Chinese medicine, talents, inheritance and innovation, industry and health service industry, culture, open development and governance ability, the plan proposes to further improve the service system of traditional Chinese medicine, accelerate the construction of talents with characteristics of traditional Chinese medicine, continuously enhance the inheritance and innovation ability of traditional Chinese medicine, achieve positive results in the high-quality development of traditional Chinese medicine industry and health service industry, and vigorously carry forward the culture of traditional Chinese medicine, The opening-up and development of traditional Chinese medicine have been actively promoted, and the governance level of traditional Chinese medicine has been further improved. The plan comprehensively considers the key areas of TCM development such as medical treatment, scientific research, industry, education, culture and international cooperation, and puts forward ten key tasks. One is to build a high-quality and efficient TCM service system. Second, improve the health service capacity of traditional Chinese medicine. Third, build a contingent of high-quality traditional Chinese medicine talents.
Fourth, build a high-level traditional Chinese Medicine Inheritance and protection and scientific and technological innovation system. Fifth, promote the high-quality development of traditional Chinese medicine industry. Sixth, develop the health service industry of traditional Chinese medicine. Seventh, promote the prosperity and development of traditional Chinese medicine culture. Eighth, accelerate the opening-up and development of traditional Chinese medicine. Ninth, deepen the reform in the field of traditional Chinese medicine. Ten is to strengthen the support and guarantee for the development of traditional Chinese medicine.
The plan proposes to build a high-level scientific and technological innovation system of traditional Chinese medicine. The plan puts forward that accelerating the construction of a scientific and technological innovation system of traditional Chinese medicine in line with the characteristics of traditional Chinese medicine is an important field of scientific and technological innovation and an important content of building an innovative country. It is also an important measure to build a healthy China and enhance the driving role of science and technology in the protection of people’s health and the development of undertakings and industries. The State Administration of traditional Chinese medicine and the Ministry of science and technology jointly formulated and issued the implementation plan for promoting the construction of scientific and technological innovation system of traditional Chinese medicine. During the 14th Five Year Plan period, the scientific and technological resources of traditional Chinese medicine will be integrated and optimized to build a three-level “National industry local” scientific and technological innovation system of traditional Chinese medicine. First, vigorously promote the construction of innovation base of traditional Chinese medicine. In the national key laboratory system, support the construction of national key laboratories in important fields such as traditional Chinese medicine theory, traditional Chinese medicine resources, modern traditional Chinese medicine innovation and traditional Chinese medicine efficacy evaluation. Focusing on major chronic diseases, dominant diseases of traditional Chinese medicine and characteristic therapies such as acupuncture and moxibustion, we will build a number of national clinical medicine research centers of traditional Chinese medicine and their collaborative innovation networks. Focusing on the breakthrough of key technologies and core equipment restricting the development of traditional Chinese medicine, a number of national engineering research centers have been built in the direction of traditional Chinese medicine standardization, clinical efficacy and safety evaluation of traditional Chinese medicine, quality control of traditional Chinese medicine, research and development of new traditional Chinese medicine, intelligent diagnosis and treatment of traditional Chinese medicine. Second, we will strengthen research in key areas. Increase support for scientific and technological innovation of traditional Chinese medicine in national scientific and technological plans such as scientific and technological innovation 2030 – major projects and key R & D plans. Deepen the research on major scientific issues such as the original theory of traditional Chinese medicine and the action mechanism of traditional Chinese medicine. We will carry out diagnosis, treatment and clinical research on the prevention and treatment of major, refractory, rare diseases and emerging infectious diseases with traditional Chinese medicine. Third, strengthen the construction of scientific and technological talents. We will strengthen the training and introduction of leading talents and innovation teams, improve the incentive and evaluation mechanism for scientific and technological talents, and encourage researchers of traditional Chinese medicine to start businesses and innovate. Fourth, promote the transformation of research results. Build a number of incubation and transformation bases for scientific and technological achievements of traditional Chinese medicine. Support traditional Chinese medicine hospitals to strengthen cooperation and share resources with enterprises, scientific research institutions and colleges and universities. Encourage colleges and universities, scientific research institutes and medical institutions to establish specialized technology transfer institutions, respect the law of scientific research of traditional Chinese medicine, give scientific research institutions and researchers greater autonomy in terms of achievement transformation income and team formation, and promote the transformation and application of excellent research achievements.
The plan proposes to improve the price of traditional Chinese medicine and medical insurance policies. The plan proposes that during the 14th Five Year Plan period, we will comprehensively promote the price reform of traditional Chinese medicine medical services, promote the improvement of traditional Chinese medicine prices and medical insurance policies, give full play to the leverage role of medical insurance in regulating medical service behavior and guiding the allocation of medical resources, and promote the characteristic advantages of traditional Chinese medicine. First, fully consider the characteristics of traditional Chinese medicine medical services, establish a health technology evaluation system of traditional Chinese medicine medical services based on clinical value and technical labor value, and optimize the price policy of traditional Chinese medicine medical services. The second is to implement the dynamic adjustment mechanism of medical service prices, bring qualified TCM medical service items into the scope of price adjustment, straighten out the price comparison relationship of medical services, and alleviate the structural contradiction of medical service prices. Third, improve the market competition environment and guide the formation of a quality-oriented market price mechanism for traditional Chinese medicine. Fourth, support the inclusion of traditional Chinese medicine medical service items and traditional Chinese medicine with advantages in curative effect and cost into the payment scope of basic medical insurance according to regulations, and reasonably determine category A and category B of the catalogue by comprehensively considering factors such as effectiveness and economy. The prepared pieces and preparations of traditional Chinese medicine processed and used by medical institutions shall be subject to independent pricing, and those that meet the conditions shall be included in the payment scope of basic medical insurance according to procedures. Fifth, select and release more advantageous diseases of traditional Chinese medicine, include them in the category of payment by disease, and encourage the implementation of the same disease, the same effect and the same price of traditional Chinese and Western medicine. General TCM diagnosis and treatment projects can continue to be paid according to the project. We will pay per capita for some chronic diseases, improve relevant technical specifications, and encourage and guide grass-roots medical and health institutions to provide appropriate traditional Chinese medicine services. Sixth, strengthen the connection between basic medical insurance and commercial health insurance, encourage commercial insurance institutions to develop traditional Chinese medicine characteristic health insurance products such as treatment and prevention of diseases, establish an information docking mechanism between insurance companies and traditional Chinese medicine institutions, and support the provision and use of traditional Chinese medicine services. Seventh, carry out the pilot of medical insurance supporting the inheritance, innovation and development of traditional Chinese medicine, encourage and promote more local governments and medical insurance departments to try first, and formulate policy documents on medical security supporting the inheritance, innovation and development of traditional Chinese medicine.
Investment suggestion: the implementation of the plan is conducive to establish and improve the evaluation index system and institutional mechanism suitable for the inheritance, innovation and development of traditional Chinese medicine from the national strategic level, better solve the difficulties and problems faced by the development of traditional Chinese medicine, fully mobilize local and social forces, and form the joint efforts of relevant departments, local Party committees and governments to promote the revitalization and development of traditional Chinese medicine. The implementation of the objectives, indicators, key tasks and major policies and measures of the plan will promote the development of traditional Chinese medicine industry into a new stage, make the achievements of traditional Chinese medicine development better benefit the broad masses, and provide strong support for comprehensively promoting the construction of a healthy China and better ensuring the health of the people. It is suggested to pay attention to the innovative drug targets of traditional Chinese medicine: Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) ( Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) ), Jiangsu Kanion Pharmaceutical Co.Ltd(600557) ( Jiangsu Kanion Pharmaceutical Co.Ltd(600557) ), etc; Target of brand traditional Chinese medicine: Beijing Tongrentang Co.Ltd(600085) ( Beijing Tongrentang Co.Ltd(600085) ), Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) ( Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) ), Yunnan Baiyao Group Co.Ltd(000538) ( Yunnan Baiyao Group Co.Ltd(000538) ), etc; Target of traditional Chinese medicine formula granules: China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) ( China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) ), Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) ( Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) ), etc.
Risk warning: policy uncertainty risk; Price fluctuation risk of raw materials of traditional Chinese medicine; Increased market competition and risks.
